Premium
EFFECTS OF A DAIDZEIN‐RICH ISOFLAVONE AGLYCONE EXTRACT ON BODY COMPOSITION IN OVERWEIGHT PREMENOPAUSAL JAPANESE WOMEN
Author(s) -
Sato Yoshiaki,
Higuchi Akira,
Pan Weijun
Publication year - 2007
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2007.04786.x
Subject(s) - bioelectrical impedance analysis , endocrinology , medicine , adiponectin , triglyceride , leptin , daidzein , body mass index , overweight , chemistry , adipose tissue , calorie , cholesterol , obesity , genistein , insulin resistance
SUMMARY1 We evaluated the effects of AglyMax (Nichimo Co. Ltd, Tokyo, Japan), a daidzein‐rich isoflavone aglycone (IFA) extract, on body composition in 21 overweight premenopausal Japanese women with a body mass index (BMI) 30 kg/m 2 . All subjects consumed controlled‐energy diets (CED) at 30 kcal/kg per day with 20% of total calories from protein, 55% from carbohydrate and 25% from fat, in which less than 20% of total calories was provided by animal fat. Subjects were randomized into two groups, the treatment group receiving 80 mg IFA/day for 8 weeks (AglyMax) and the other consuming CED without tablets (control). Plasma lipids (total cholesterol, high‐density lipoprotein–cholesterol, low‐density lipoprotein–cholesterol and triglyceride), leptin and adiponectin levels were measured at baseline and at 8 weeks. Bodyweight and body composition (body fat mass, skeletal muscle mass, visceral fat) were measured at baseline and at 8 weeks by bioelectrical impedance analysis (BIA). 2 All subjects completed the study. At the end of the study, average bodyweight was reduced by 1.4% in the control group and by 2.6% in the AglyMax group. Average BMI was reduced by 1.4 and 2.7% in the control and AglyMax groups, respectively. Visceral fat, as measured by BIA, was significantly reduced in the control and AglyMax groups by 4.8 and 7.5%, respectively. In the AglyMax group, plasma leptin secretion was significantly decreased from 22.5 to 12.1 ng/mL and plasma adiponectin secretion was significantly increased from 8.1 to 12.2 ng/mL comparing values at baseline with those at 8 weeks ( P < 0.05). Plasma adiponectin secretion was also significantly higher in the AglyMax group than in the control group ( P < 0.05) at 8 weeks. In the control group, plasma leptin and adiponectin secretion were not significantly different between baseline and at 8 weeks. 3 The CED was effective in lowering bodyweight and body fat mass. The administration of AglyMax as a dietary supplement further reduced bodyweight and body fat mass. Taking AglyMax was associated with a beneficial lowering of bodyweight, BMI and visceral fat in overweight premenopausal women by decreasing plasma leptin secretion and increasing plasma adiponectin secretion.